Skip to main content
SpringerLink
Log in

Current concepts in transarterial chemoembolization of hepatocellular carcinoma

  • Published:
Abdominal Imaging Aims and scope Submit manuscript

Abstract

Transarterial chemoembolization (TACE) has the potential to improve survival in patients with intermediate stage hepatocellular carcinoma (HCC). Careful selection of patients is mandatory to gain survival benefit and safe quality of life. Basic principles of TACE in HCC include selective treatment via intrahepatic and extrahepatic arteries, proper management of side effects and continuation of treatment guided by imaging. After conventional TACE, based on delivery of cytotoxic drugs emulsified in iodized oil and embolization of various types of particles, has been used for more than 20 years, the new concept of drug-eluting microspheres has been introduced. This technology effectively combines enhanced local drug delivery and ischemic embolization effects. Clinical studies showed intensified local necroses and reduced systemic toxic side effects compared to conventional TACE. Embolization of HCC with sub-100 μm particles penetrating deeply into the tumor vascular bed is another promising new option. Very effective devascularization of HCC nodules has been shown after 40 μm bland embolizations, however, potential risks like passage of particles into hepatic veins and systemic circulation have to be considered. Today the indication for TACE in intermediate stage HCC patients is widely accepted; however, there is no clear methodical standard so far. Further studies are necessary to define how to adapt various available methods to individual HCC and patients characteristics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, et al. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108

    Article  PubMed  Google Scholar 

  2. Di Bisceglie AM (2002) Epidemiology and clinical presentation of hepatocellular carcinoma. J Vasc Interv Radiol 13(Suppl):S169–S171

    Article  PubMed  Google Scholar 

  3. Bosch FX, Ribes J, Borras J (1999) Epidemiology of primary liver cancer. Semin Liver Dis 19:271–285

    Article  PubMed  CAS  Google Scholar 

  4. Schwartz M, Roayaie S, Konstadoulakis M (2007) Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 4(7):424–432

    Article  PubMed  CAS  Google Scholar 

  5. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907–1917

    Article  PubMed  Google Scholar 

  6. Clark HP, Carson WF, Kavanagh PV, et al. (2005) Staging and current treatment of hepatocellular carcinoma. Radiographics 25(Suppl):S3–S23

    Article  PubMed  Google Scholar 

  7. Bruix J, Sala M, Llovet JM (2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 125(5 Suppl):179–188

    Article  Google Scholar 

  8. Wible BC, Rilling WS, Drescher P, et al. (2010) Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization. J Vasc Interv Radiol 21:1024–1030

    Article  PubMed  Google Scholar 

  9. Llovet JM, Real MI, Montana X, et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359:1734–1739

    Article  PubMed  Google Scholar 

  10. Lo CM, Ngan H, Tso WK, et al. (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171

    Article  PubMed  CAS  Google Scholar 

  11. Trinchet JC, et al. (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma (Group d etude et de traitement du carcinoma hepatocellulaire). N Engl J Med 332:1256–1261

    Article  Google Scholar 

  12. Miyayama S, Yamashiro M, Okuda M, et al. (2010) The march of extrahepatic collaterals: analysis of blood supply to hepatocellular carcinoma located in the bare area of the liver after chemoembolization. CardioVasc Intervent Radiol 33:513–522

    Article  PubMed  Google Scholar 

  13. Marelli L, Stigliano R, Triantos C, et al. (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. CardioVasc Interv Radiol 30:6–25

    Article  Google Scholar 

  14. Eisenhauer EA, Therasse P, Bogaerts J, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  PubMed  CAS  Google Scholar 

  15. Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the study of the liver. J Hepatol 35:421–430

    Article  PubMed  CAS  Google Scholar 

  16. Llovet MJ, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48:20–37

    Article  Google Scholar 

  17. Huppert P, Lauchart W, Duda SH, et al. (2004) Chemoembolization of hepatocellular carcinoma: which factors determine therapeutic response and survival? Fortschr Roentgenstr 176:375–385

    Article  CAS  Google Scholar 

  18. Lewis AL, Gonzales MV, Leppard SW, et al. (2007) Doxorubicin eluting beads-1: effects of drug loading on beads characteristics and drug distribution. J Mater Sci Mater Med 18:1691–1696

    Article  PubMed  CAS  Google Scholar 

  19. Jordan O, Denys A, De Baere T, et al. (2010) Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead on hepasphere loaded with doxorubicin and irinotecan. J Vasc Interv Radiol 21:1084–1090

    Article  PubMed  Google Scholar 

  20. Poon RT, Tso WK, Pang RW, et al. (2007) A phase I/II trial of chemoembolisation for hepatocellular carcinoma using a novel intraarterial drug-eluting bead. Clin Gastroenterol Hepatol 5:1100–1108

    Article  PubMed  CAS  Google Scholar 

  21. Varela M, Real MI, Burrel M, et al. (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474–481

    Article  PubMed  CAS  Google Scholar 

  22. Malagari K, Pomoni M, Kelekis A, et al. (2010) Prospective randomized comparison of chemoembolization with Doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33:541–551

    Article  PubMed  Google Scholar 

  23. Lammer J, Malagari K, Vogl T, et al. (2010) Prospective randomized study of doxorubicin-eluting bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol 33:41–52

    Article  Google Scholar 

  24. Grosso M, Vignali C, Quaretti P, et al. (2008) Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol 31:1141–1149

    Article  PubMed  Google Scholar 

  25. Dhanasekaran R, Kooby DA, Staley CA, et al. (2010) Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocellular carcinoma (HCC). J Surg Oncol 101:476–480

    PubMed  Google Scholar 

  26. Bonomo G, Pedicini V, Monfardini L, et al. (2010) Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol 33:552–559

    Article  PubMed  Google Scholar 

  27. Stampfl S, Bellemann N, Stampfl U, et al. (2008) Inflammation and recanalization of four different spherical embolization agents in the porcine kidney model. J Vasc Interv Radiol 19:577–586

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diagnostic and Interventional Radiology, Klinikum Darmstadt GmbH, Grafenstrasse 9, 64283, Darmstadt, Germany

    Peter Huppert

Authors
  1. Peter Huppert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Huppert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huppert, P. Current concepts in transarterial chemoembolization of hepatocellular carcinoma. Abdom Imaging 36, 677–683 (2011). https://doi.org/10.1007/s00261-011-9755-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-011-9755-4

Keywords

Search

Navigation